The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2312-2320

  Ambrosini, Grazia ^a   Seelman, Sharon L ^a   Qin, Li Xuan ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DNA TOPOISOMERASE; FLAVOPIRIDOL; IRINOTECAN; MUTANT PROTEIN; POISON; PROTEIN P53; RAD51 PROTEIN; SERINE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA MICROARRAY; DNA REPAIR; DOWN REGULATION; DRUG INHIBITION; DRUG POTENTIATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 9; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; DRUG SYNERGISM; FLAVONOIDS; HCT116 CELLS; HUMANS; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; RAD51 RECOMBINASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 42049101633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2395     Document Type: Article

References (44)

1. Bible KC, Bible RH, Jr., Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-28.
2. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992;84:1736-40.
3. Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 1997;3:1467-72.
4. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
5. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7:4209-19.
6. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-45.
7. Gatz SA, Wiesmuller L. p53 in recombination and repair. Cell Death Differ 2006;13:1003-16.
8. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677-9.
9. Tibbetts RS, Brumbaugh KM, Williams JM, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999;13:152-7.
10. Restle A, Janz C, Wiesmuller L. Differences in the association of p53 phosphorylated on serine 15 and key enzymes of homologous recombination. Oncogene 2005;24:4380-7.
11. Linke SP, Sengupta S, Khabie N, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003;63:2596-605.
12. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996;87:757-66.
13. Gupta RC, Bazemore LR, Golub EI, Radding CM. Activities of human recombination protein Rad51. Proc Natl Acad Sci U S A 1997;94:463-8.
14. Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res 2002;62:219-25.
15. Yoon D, Wang Y, Stapleford K, Wiesmuller L, Chen J. P53 inhibits strand exchange and replication fork regression promoted by human Rad51. J Mol Biol 2004;336:639-54.
16. Sengupta S, Linke SP, Pedeux R, et al. BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 2003;22:1210-22.
17. Arias-Lopez C, Lazaro-Trueba I, Kerr P, et al. p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep 2006;7:219-24.
18. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
19. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3: Article3.
20. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 2004;64:6635-44.
21. Prasad R, Liu Y, Deterding LJ, et al. HMGB1 is a cofactor in mammalian base excision repair. Mol Cell 2007;27:829-41.
22. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-9.
23. Cahill D, Connor B, Carney JP. Mechanisms of eukaryotic DNA double strand break repair. Front Biosci 2006;11:1958-76.
24. Durant ST, Nickoloff JA. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle 2005;4:1216-22.
25. Lu X, Burgan WE, Cerra MA, et al. Transcriptional signature of flavopiridol-induced tumor cell death. Mol Cancer Ther 2004;3:861-72.
26. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002;8:3527-38.
27. Sambol EB, Ambrosini G, Geha RC, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006;66:5858-66.
28. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci U S A 1991;88:9979-83.
29. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR. Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 1992;20:4083-7.
30. Shiio Y, Yamamoto T, Yamaguchi N. Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci U S A 1992;89:5206-10.
31. Li DW, Liu JP, Schmid PC, et al. Protein serine/threonine phosphatase-1 dephosphorylates p53 at Ser-15 and Ser-37 to modulate its transcriptional and apoptotic activities. Oncogene 2006;25:3006-22.
32. Roy S, Tenniswood M. Site specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 2006;282:4765-71.
33. Crescenzi E, Palumbo G, Brady HJ. Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res 2005;11:8158-71.
34. Lundin C, Schultz N, Arnaudeau C, Mohindra A, Hansen LT, Helleday T. RAD51 is involved in repair of damage associated with DNA replication in mammalian cells. J Mol Biol 2003;328:521-35.
35. Sonoda E, Sasaki MS, Buerstedde JM, et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998;17:598-608.
36. Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y. Rad51 siRNA delivered by HVJ envelope vector enhances the anti-cancer effect of cisplatin. J Gene Med 2005;7:1044-52.
37. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001;29:1534-8.
38. Abe H, Wada M, Kohno K, Kuwano M. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res 1994;14:1807-10.
39. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003;193:91-109.
40. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
41. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001;19:1985-92.
42. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res 2001;7:1590-9.
43. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
44. Fornier MN, Rathkopf D, Shah M, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13:5841-6.